<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760600</url>
  </required_header>
  <id_info>
    <org_study_id>role of parasites in ibd ibs</org_study_id>
    <nct_id>NCT04760600</nct_id>
  </id_info>
  <brief_title>Role of Parasitic Infection in Inflammatory Bowel Disease and Irritable Bowel Syndrome</brief_title>
  <official_title>Role of Parasitic Infection in Inflammatory Bowel Disease and Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Role of parasitic infection in Inflammatory bowel disease and Irritable bowel The burden of&#xD;
      the parasitic disease is in-direct relation with the health and nutritional status of the&#xD;
      host, inducing not only parasite-specific immunity but also can modify the host's immune&#xD;
      responses . Many parasites can imitate inflammatory bowel disorders and some studies showed&#xD;
      that infection with parasites can improve disorders like IBD or moderate the symptoms of&#xD;
      inflammatory bowel disorders . Even though, many studies have shown that gastrointestinal&#xD;
      infection is an important risk factor for the development of IBS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Detect the prevalence of parasite/s associated with Inflammatory bowel diseases (IBD)&#xD;
           and Irritable bowel syndrome (IBS) in comparison with control subjects.&#xD;
&#xD;
        2. Evaluating the effect of the parasite on the course and prognosis of the diseases.&#xD;
&#xD;
        3. Evaluating the effect of the antiparasitic drugs on the course and prognosis of the&#xD;
           diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detect the prevalence of parasite/s associated with Inflammatory bowel diseases (IBD) and Irritable bowel syndrome (IBS) in comparison with control subjects.</measure>
    <time_frame>baseline</time_frame>
    <description>Detect the prevalence of parasite/s associated with Inflammatory bowel diseases (IBD) and Irritable bowel syndrome (IBS) in comparison with control subjects.by making stool analysis and clinical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure the effect of the antiparasitic drugs on the course and prognosis of the diseases</measure>
    <time_frame>baseline</time_frame>
    <description>giving the patient antiparasitic drug and measure the effect of anti parasitic drug on course and prognosis of disease</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Parasite IBS IBD</condition>
  <arm_group>
    <arm_group_label>IBD GROUPS</arm_group_label>
    <description>PATIENT WITH IBD DISEASE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBS GROUP</arm_group_label>
    <description>PATIENT WIT IBS DISEASE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL 1</arm_group_label>
    <description>CONTROL WITH POSITIVE PARASITIC INFECTION AN POSITIVE GIT SYMTOMS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL2</arm_group_label>
    <description>HEALTHY VOLUNTEARS</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosis of IBD will be confirmed using standard clinical, endoscopic, radiographic and&#xD;
        pathological criteria according to the Montreal classification of the extent and severity&#xD;
        of IBD The activity of the disease will be measured using the Mayo Clinic score consisting&#xD;
        of 4 items: stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy, and&#xD;
        patient's functional assessment Diagnosis of IBS will depend on Rome IV criteria Recurrent&#xD;
        abdominal pain on average at least 1 day/week in the last 3 months, associated with two or&#xD;
        more of the following criteria: Related to defecation; Associated with a change in the&#xD;
        frequency of stool and/ or Associated with a change in the form (appearance) of stool.&#xD;
&#xD;
          -  any patient who received antipiotic or antiparasitic drug within the past 4 weeks not&#xD;
             taken&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of IBD will be confirmed using&#xD;
&#xD;
               1. standard clinical,&#xD;
&#xD;
               2. endoscopic,&#xD;
&#xD;
               3. radiographic and4 pathological criteria according to the Montreal classification&#xD;
                  of the extent and severity of IBD&#xD;
&#xD;
          -  Diagnosis of IBS will depend on Rome IV criteria&#xD;
&#xD;
               1. Recurrent abdominal pain on average at least 1 day/week in the last 3 months,&#xD;
&#xD;
               2. associated with two or more of the following criteria:&#xD;
&#xD;
               3. Related to defecation;&#xD;
&#xD;
               4. Associated with a change in the frequency of stool and/ or Associated with a&#xD;
                  change in the form (appearance) of stool.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any patient who received antipiotic or antiparasitic drug within the past 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>rasha hassan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mona mostafa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>marina shawqi, md</last_name>
    <phone>01276121351</phone>
    <email>gm161059@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>lamia galal</last_name>
    <phone>01003143075</phone>
    <email>lamiazak@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Marina Gamil Shwqi</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lamia galal</last_name>
      <phone>+201003143075</phone>
      <email>lamiazak@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754014/</url>
    <description>Human Intestinal Parasites</description>
  </link>
  <link>
    <url>http://www.mendeley.com/catalogue/7d32c086-0fd2-3c70-a8f6-456b2737bdaa/?utm_source=desktop&amp;utm_medium=1.19.4&amp;utm_campaign=open_catalog&amp;userDocumentId=%7Bce3e00ed-dfc4-436d-98ea-beb2dd8f2961%7D</url>
    <description>Comparative pathobiology of the intestinal protozoan parasites giardia lamblia, entamoeba histolytica, and cryptosporidium parvum</description>
  </link>
  <link>
    <url>http://www.mendeley.com/catalogue/751a62fa-7a37-31b6-85ec-176f042b5e4d/?utm_source=desktop&amp;utm_medium=1.19.4&amp;utm_campaign=open_catalog&amp;userDocumentId=%7B7ea29a48-e517-4237-9dc4-b0d319284902%7D</url>
    <description>Opportunistic infections due to inflammatory bowel disease therapy</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996262/</url>
    <description>Prevalence of Intestinal Parasitic Infections among the Bulgarian Population Over a Three Year Period</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/14642761/</url>
    <description>Soil-transmitted helminth infections: updating the global picture</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/22586430/</url>
    <description>Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/33295611/</url>
    <description>Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>marina gamil shwqi</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parasitic Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

